In this webinar for patients and caregivers, Dr. Miriam Merad describes the fundamentals of cancer immunology, advances in immunotherapy of different types of cancer, and ongoing work to make immunotherapy an effective treatment option for more patients.
Dr. Merad is the director of the Mark and Jennifer Lipschultz Precision Immunology Institute and the Human Immune Monitoring Center at the Icahn School of Medicine at Mount Sinai in New York City. She is an internationally acclaimed expert in the biology of myeloid cells, like dendritic cells (DCs) and macrophages. She is also a member of the CRI Scientific Advisory Council, and has been a sponsor and mentor of two CRI postdoctoral fellows.
Funding for the CRI "Cancer Immunotherapy and You" webinar series is generously provided by Bristol Myers Squibb as well as Alkermes and Lilly Oncology.
Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. www.cancerresearch.org
Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.
20 июн 2024
